17 January 2003 16:48 [Source: ICIS news]
HOUSTON (CNI)--The U.S. Food and Drug Administration (FDA) has granted fast track designation to American Pharmaceutical Partners (APP) for ABI-007, a treatment for metastatic breast cancer, company officials said Friday.
The Los Angeles, California-based injectable drug specialist said it has worked closely with the FDA in a testing phase of the drug that began in 1996 and was granted the status because ABI-007, a cremophor-free nanoparticle paclitaxel, has the potential to address an unmet medical need.
Fast track designation means APP will continue to work closely with the FDA to submit a new drug application in sections rather than all components at once.
APP announced last month that testing showed ABI-007 was infused over 30 minutes without steroid pretreatment at a higher dose than Taxol, which requires steroid therapy and infusion over three hours. APP said that Taxol, manufactured by Bristol-Myers Squibb, contains cremophor and is responsible for many of the well-known side effects and administration problems that limit the dose of paclitaxel that can be delivered.
APP chairman Patrick Soon-Shiony said with fast track status the company "may be able to more quickly provide a new therapeutic approach to the treatment of metastatic breast cancer."
APP develops manufactures and markets injectable pharmaceutical products that specialize in the oncology, anti-infective and critical care markets.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
|ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index|
Asian Chemical Connections